BY ALBERT RONNING-ANDERSSON
-
Lars Rebien Sørensen loses big on a terrible day for Novo on the stock market
In late 2025, Lars Rebien Sørensen held simply over half a million shares in Novo Nordisk, which took a hefty dive on Nasdaq Copenhagen Wednesday complying with a dismal projection…
-
Management resignations cost Novo Nordisk USD 35m in 2025
In 2025, Novo Nordisk paid an overall of DKK 219.9 m (USD 34.8 m) about resignations and particular employment plans for participants of monitoring.
-
Fired Novo CEO received USD 10.3m in golden handshake
Lars Fruergaard Jørgensen was dismissed last spring after eight years at the helm of Novo Nordisk in the wake of market challenges and a sharp decline in the share price.
-
Professor: Novo Nordisk is in a predicament with new layoffs
In regards to interaction, Novo Nordisk is attempting to stay clear of a story that workers might be afraid one more round in 6 months and 9 months, according to a teacher of compa…
-
Listed Danish biotech company fights for survival after FDA rejection and failed capital raising
IO Biotech, which has significant Danish structures amongst its proprietors, is currently discovering tactical chances to make it through as a firm.
-
Former Leo Pharma boss steps down as CEO of Newbury Pharmaceuticals
Difference over tactical instructions has actually led the board of supervisors and the previous chief executive officer of Leo Pharma to end their cooperation.
-
Major drugmakers hesitant to use FDA’s new fast-track program
Numerous firms are afraid lawful dangers if fast authorizations are later on tested.
-
EMA lags behind FDA in new drugs, but overall activity level is close to record high
The European Medicines Agency recommends fewer new substances than the US, but continues to see rapid approvals and a significant focus on hormonal disorders.
-
Novo Nordisk appoints new AI boss with “bold ambitions”
The Danish pharmaceutical business marketed the setting in November in 2015, and Novo Nordisk has actually currently employed its initial AI supervisor. She originates from within …
-
Eli Lilly EVP: Strict meal requirements may limit Wegovy’s potential
Team supervisor at Eli Lilly sees restrictions for the Wegovy tablet and introduces his very own rival without the very same needs.
